Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review

NOWICKA, Emilia, OBEL, Michał, PANUCIAK, Kinga, MASTALERCZYK, Angelika, CZYŻAK, Kamila, LEJMAN, Jan, MAKOWSKA, Karolina & WIŚNIEWSKI, Wiktor. Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review. Journal of Education, Health and Sport. 2023;13(2):104-109. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2023.13.02.014

https://apcz.umk.pl/JEHS/article/view/41206

https://zenodo.org/record/7477122

The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of December 21, 2021. No. 32343.

Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical Culture Sciences (Field of Medical sciences and health sciences); Health Sciences (Field of Medical Sciences and Health Sciences).

Punkty Ministerialne z 2019 - aktualny rok 40 punktów. Załącznik do komunikatu Ministra Edukacji i Nauki z dnia 21 grudnia 2021 r. Lp. 32343. Posiada Unikatowy Identyfikator Czasopisma: 201159.

Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).

© The Authors 2022;

This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.

(http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 06.12.2022. Revised: 21.12.2022. Accepted: 23.12.2022.

Poly ADP-ribose polymerase (PARP) inhibitors- new therapeutic strategies in Acute Myeloid Leukemia: a literature review

Affiliation:

Emilia Nowicka¹ e.nowicka22@gmail.com; https://orcid.org/0000-0002-2743-1551

Michał Obel²  michalobel3@gmail.com; https://orcid.org/0000-0003-1237-8732

Kinga Panuciak¹ kinga.panuciak26@gmail.com; https://orcid.org/0000-0001-9014-5171

Angelika Mastalerczyk¹ ngmastaler@gmail.com; https://orcid.org/0000-0002-7576-2152

Kamila Czyżak¹ kamilacz1905@gmail.com; https://orcid.org/0000-0002-8866-5810

Jan Lejman¹ lejmjan@gmail.com; https://orcid.org/0000-0002-8065-2839

Karolina Makowska¹ makowska.karolinaa@gmail.com; https://orcid.org/0000-0001-5467-3137

Wiktor Wiśniewski³ victor.wisniewsky4@gmail.com; https://orcid.org/0000-0001-5845-8012

1. Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin,  

A. Racławickie 1, 20-059 Lublin

2.Medical University of Lublin, A. Racławickie 1, 20-059 Lublin

3.EMC Clinic, Łowiecka Street 24, 50-220 Wrocław

Abstract

The use of poly (ADP-ribose) polymerase (PARP) inhibitors has recently increased as a result of demonstrating their superior efficacy compared to traditional chemotherapy in various cancer subtypes in many preclinical studies and clinical trials. A better understanding of the molecular mechanisms of PARP and their underlying foci that can be used as screening markers for potential new therapeutic options would aid rational treatment strategies and improve long-term patient outcomes. The available data on acute leukemia suggest potential windows for effective treatment of PARPi in disease subgroups. In this review, we summarize the current advances in the most common PARP-based adjuvant therapies and combination strategies for the treatment of acute leukemia and discuss the future prospects and challenges of therapy with PARP inhibitors. We also discuss reports describing an increased risk of cancer treatment in patients receiving PARP inhibitors for solid tumors.

The research material were publications, the search was carried out using a combination of keywords such as: "PARP inhibitor", "acute leukemia", "therapy", "PARP clinical trials". The first step was to find relevant publications from the last 15 years. The second step was to review the publications found.

Studies have shown that PARP inhibitors play an increasing role in the treatment of leukemia. In addition, focusing research efforts on identifying the most effective drug combinations and sequences could help to further shape the role of PARPi in the treatment of acute myeloid leukemia (AML).

Keywords: PARP  inhibitor; Drug targets; Combination therapies; Acute leukemia; Acute Myeloid Leukemia